We used in vitro development examines and in vivo xenograft models to test the impact of again pyrimidine union hindrance on prostate cell lines. Here, we show that PTEN-inadequate prostate malignancy cell lines are helpless to hindrance of all over again pyrimidine combination by leflunomide. Tumor development hindrance was seen in vitro and in vivo following leflunomide treatment, and is likely because of a staggering gathering of DNA harm.
Our work features that engineered lethality emerges upon the mix of PTEN misfortune and leflunomide therapy in prostate malignancy, and may introduce a helpful open door for this patient populace.
Reference link- https://www.nature.com/articles/s41391-020-0251-1
